



**Item 9.01. Financial Statements and Exhibits.**

The following document extends the period of the SWO until November 17, 2008. It is being filed with this Form 8-K solely because it was inadvertently omitted from our Form 10-Q filed on October 31, 2008. The total contract amount remains unchanged (\$102,661,429). The contract completion date remains unchanged (December 31, 2010).

**Exhibit**

**Number**

**Description**

10.1	Amendment of Solicitation/Modification of Contract.
------	---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**BioCryst Pharmaceuticals, Inc.**

Date: November 7, 2008

By: /s/ Michael A. Darwin

Name: Michael A. Darwin

Title: Vice President Finance

**EXHIBIT INDEX**

<b>Exhibit Number</b>	<b>Description</b>
10.1	Amendment of Solicitation/Modification of Contract.